banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Ashley  Basiorka

Ashley Basiorka

Ashley Basiorka



On January 17, 2017, Dr. Ashley Basiorka successfully defended her doctoral dissertation. Pictured with her committee and invited chair; from left: committee member P.K. Epling-Burnette, invited chair Daniel Starczynowski from Cincinnati Children's Hospital, Ashley, Major Professor Alan List, committee members Sheng Wei and Javier Pinilla Ibarz. Dr. Basiorka has joined the Prescott Medical Communications Group as an Associate Medical Writer.

Dr. Basiorka's publication record while in the Cancer Biology Program:

Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, Komrokji R, Djeu J, List A, Wei S. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017 Feb 10. doi: 10.1038/leu.2017.21.PMID: 28096534

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 Inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Oct 13. pii: blood-2016-07-730556. PMID: 27737891

Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Front Oncol. 2016 Jun 16;6:151. doi: 10.3389/fonc.2016.00151. eCollection 2016. Review. PMID: 27379212

Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Soko Ll, Komrokji RS, Reuther GW, Wei S, Tavernier J, and Lis AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Research. 2016 Jun 15;76(12):3531-40. doi: 10.1158/0008-5472.CAN-15-1756. Epub 2016 Apr 6. PMID: 27197154

McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Sep 25. [Epub ahead of print] PMID: 26416416

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar 13;5:e291. doi: 10.1038/bcj.2015.11. PMID:25768405

McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014 Dec 3;9(12):e114249. doi: 10.1371/journal.pone.0114249. eCollection 2014.PMID:25469886

Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16127-32. doi: 10.1073/pnas.1311055110. PMCID:PMC3791697